Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award - Priority Announcement: Osteoporosis (SHOPP)

University of Toronto

$8,750.00

Cost-effective strategies for osteoporosis drug coverage in Canada.

FY 2009-10

Summary
Osteoporosis is a major public health concern in Canada resulting in increased rates of fracture. With the aging of our population, the burden and cost of illness due to osteoporosis and its related fractures is expected to increase substantially. Although a range of osteoporosis drug therapies have been approved for fracture prevention, levels of public coverage vary greatly across Canada. As a result, an inequity in patient access to critical osteoporosis therapies exists. To better understand and potentially bridge the gap in patient access to osteoporosis treatments, inter-provincial variations in reimbursement of osteoporosis medications needs to be assessed. Using methods of economic modeling, we will evaluate various economic circumstances by which provinces may consider reimbursement of specific therapies. We will apply results from this study to develop a framework that can inform decision makers of cost-effective strategies for covering new osteoporosis therapies in Canada. Ultimately, results from this study may have important implications in maintaining healthcare costs within reasonable limits, while ensuring patient access to appropriate and efficacious osteoporosis treatments.
Program
Master's Award - Priority Announcement: Osteoporosis (SHOPP)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
203010
Name
Nikitovic Milica
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Osteoporosis Canada (Toronto, Ontario)
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Canada Graduate Scholarships Master's Awards B
Projecttitle
Cost-effective strategies for osteoporosis drug coverage in Canada.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$8,750
Cihrequipment2
$0
Programname2
Master's Award - Priority Announcement: Osteoporosis (SHOPP)
Keyworddelim
Cost Effectiveness; Drug Accessibility; Health Policy; Osteoporosis; Pharmacoeconomics; Pharmacoepidemiology; Reimbursement
Abstract
Osteoporosis is a major public health concern in Canada resulting in increased rates of fracture. With the aging of our population, the burden and cost of illness due to osteoporosis and its related fractures is expected to increase substantially. Although a range of osteoporosis drug therapies have been approved for fracture prevention, levels of public coverage vary greatly across Canada. As a result, an inequity in patient access to critical osteoporosis therapies exists. To better understand and potentially bridge the gap in patient access to osteoporosis treatments, inter-provincial variations in reimbursement of osteoporosis medications needs to be assessed. Using methods of economic modeling, we will evaluate various economic circumstances by which provinces may consider reimbursement of specific therapies. We will apply results from this study to develop a framework that can inform decision makers of cost-effective strategies for covering new osteoporosis therapies in Canada. Ultimately, results from this study may have important implications in maintaining healthcare costs within reasonable limits, while ensuring patient access to appropriate and efficacious osteoporosis treatments.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nikitovic, Milica
Approvedterm
1 an 0 mois
Cihrcontribution2
SPIR~ $8,750~ $0~